U.S. markets closed

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Precio retrasado. Moneda en EUR.
Añadir a la lista de seguimiento
29.96-0.27 (-0.89%)
Al cierre: 05:35PM CEST

Fresenius SE & Co. KGaA

Else-Kroener-Strasse 1
Bad Homburg vor der Höhe 61352
Germany
49 6172 6080
https://www.fresenius.com

Sector(es)Healthcare
IndustriaMedical Care Facilities
Empleados a tiempo completo190,863

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Michael SenCEO, President & Chairman of Management Board of Fresenius Management SE4.09MN/D1968
Ms. Sara Lisa HennickenCFO & Member of the Management Board - Fresenius Management SE1.55MN/D1980
Mr. Pierluigi AntonelliMember of Management Board of Fresenius Management SE & CEO of Fresenius Kabi2MN/DN/D
Dr. Michael Sven Moser Ph.D.Member of Management Board of Fresenius Management SE1.2MN/D1978
Mr. Robert MollerMember of the Management Board of Fresenius Management SE1.15MN/D1971
Mr. Markus GeorgiSenior Vice President of Investor RelationsN/DN/DN/D
Matthias LinkSenior Vice President Corporate CommunicationsN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Gestión corporativa

La calificación ISS Governance QuickScore de Fresenius SE & Co. KGaA a partir del 1 de julio de 2024 es 2. Las puntuaciones principales son Auditoría: 1; Junta: 4; Derechos del accionista: 1; Compensación: 2.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.